Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Part of paid clinical trials in St Louis, Missouri.

Sponsor
AstraZeneca
Study ID
NCT07427394
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Breast Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camizestrant — DRUG
    Camizestrant will be administered orally.
  • Atirmociclib — DRUG
    Atirmociclib will be administered orally.

Study Details

A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

Key Dates

Start date
May 6, 2026
Status verified
May 2026
Primary completion
Dec 3, 2027
Completion
Dec 3, 2027

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camizestrant + Atirmociclib
    Participants will receive a single dose of atirmociclib on Day -1 followed by combination of camizestrant and atirmociclib from Day 1.

Primary Outcome Measure

Number of participants with adverse events (AEs) and serious AEs [ Time Frame: Up to Post-Treatment Follow up (Day 30 Post Dose) ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Research SiteSt LouisMissouri63108-
Research SiteEast ProvidenceRhode Island02915-
Research SiteNashvilleTennessee37203-

Find similar trials in St Louis, MO

By research site
Research Site· St Louis, MOResearch Site· East Providence, RIResearch Site· Nashville, TN

Related Studies